SecBot SecBot

EBS

Emergent BioSolutions Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001367644 Biotech & Drug Discovery
$5.81 +0.02 (+0.35%)
Nov 16 4:00 PM ET · prev $5.79
Market cap
$302.3M
Small cap
Consensus
Buy
71% Buy or better · 7 analysts
Median target
$10.00
+72% · range $10.00–10.00
1 year
−42.5%
from $10.10 · Nov 17
30 days
−8.6%
from $6.36
52-week range
$4.45–13.90
−58% from high · low Aug 11
Avg volume 20D
1.07M
Nov 3 spike 3.07M
Short interest
10.08M
≈19.6% of shares · +4.1%
Days to cover
10.1
at average volume
Insider net
−$723.0K
0 buyers · 5 sellers · since Mar 3
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 1 bearish · 0 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 3/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $723.0K.

  • InstitutionsMIXED

    Q3 2026: 21 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    5 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.280 → −$0.164 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +4.1% to 10.08M shares. 10.1 days to cover, ≈19.6% of shares.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCDOUBLED732,648$4.8M
FEDERATED HERMES, INC.TRIM470,739$3.1M
Russell Investments Group, Ltd.TRIM467,420$3.1M
PANAGORA ASSET MANAGEMENT INCADD452,516$3.0M
Squarepoint Ops LLCDOUBLED317,367$2.1M
TRUIST FINANCIAL CORPDOUBLED230,092$1.5M
Quantinno Capital Management LPDOUBLED110,325$728.1K
Creative PlanningADD109,027$719.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 71% rate it Buy or better
Strong Buy1Buy4Hold1Sell1Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +72%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Washington

Corporate Lobbying

39 lobbying filings and 6 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$723.0K
sold · 5 insiders
DateInsiderTypeValue
Oct 7, 2026
DeGolyer Donald W
Director
Oct 7, 2026
SELL$126.2K
Oct 1, 2026
Williams Paul Anthony
SVP, Products Business
Oct 1, 2026
SELL$19.6K
Jul 1, 2026
Williams Paul Anthony
SVP, Products Business
Jul 1, 2026
SELL$25.2K
Jun 8, 2026
Hartzel William
SVP, Bioservices
Jun 8, 2026
TAX W/H$13.9K
Jun 8, 2026
Glessner Coleen
EVP, Quality & Ethics, and CPL
Jun 8, 2026
TAX W/H$16.1K
Jun 8, 2026
LINDAHL RICHARD S
EVP, Chief Financial Officer
Jun 8, 2026
TAX W/H$31.7K
Jun 8, 2026
Williams Paul Anthony
SVP, Products Business
Jun 8, 2026
TAX W/H$5.6K
May 1, 2026
Zoon Kathryn C
Director
May 1, 2026
SELL$9.5K

Earnings setup

Estimates
−$0.16
EPS estimate, this quarter
−159%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.16-$0.22–-$0.11-107.2%$137.7M
Next Q-$0.53-$0.53–-$0.53-1225.0%$175.0M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
10,080,407
shares short
+4.1%
vs prior settlement
10.1
days to cover
≈19.6%
of shares outstanding
Trading halts
Nov 3, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 3, 2026 Trading halt
Halt Resumed: EBS, trading resumed after M (Volatility Trading Pause)
Halted 2026-11-03T14:32:25.000Z | Resumed 2026-11-03T14:37:25.000Z
Oct 7, 2026 Insider
DeGolyer Donald W sold 17,800 shares
Director @ $7.09 ($126.2K)
Oct 1, 2026 Insider
Williams Paul Anthony sold 3,000 shares
SVP, Products Business @ $6.53 ($19.6K)
Sep 30, 2026 Inst.
FMR LLC · DOUBLED
732,648 shares ($4.8M)
Sep 30, 2026 Inst.
FEDERATED HERMES, INC. · TRIM
470,739 shares ($3.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
9 drugs tracked · Drug pipeline →
Recent

SecBot reports

18 filings · 5 press releases · 1 bullish · 2 bearish · 1 mixed · 14 neutral
All EBS filing & press-release reports (23)